Biography
Dr. Sharon Benzeno is the Chief Commercial Officer, Immune Medicine and leads the Drug Discovery group of Adaptive Biotechnologies, a commercial stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Before joining Adaptive in 2014, Sharon was Senior Director at Elsevier Inc., a healthcare informatics company. Prior to Elsevier, Sharon coled the oncology business unit at Capgemini SE, a consulting and technology services company. Sharon came to Elsevier from Capgemini, where she served in a variety of management roles at AstraZeneca plc. Sharon holds a PhD in Biomedical Sciences from New York University School of Medicine, an MBA in Finance and Leadership from New York University Stern School of Business and a BA in Biochemistry from New York University. Sharon completed a postdoctoral fellowship in cancer biology at the University of Pennsylvania Abramson Cancer Center.

Emerging Therapeutics Showcase:
Adaptive Biotech

Biography
Dr. Orr has over 20 years experience in the fields of immunology and biotechnology. She focused her career on the design of polymer based immunotherapy. Shira holds a PhD in biotechnology engineering and completed her postdoc at Harvard Medical School.

Talk
The Revolution in Drug Delivery Using Bionanopolymer and AI
Revolutionizing the world of gene therapy through the development of polymerbased nanoparticles for targeted delivery. By harnessing the power of nanotechnology, Shira will discuss how her discovery overcomes the challenges associated with traditional gene therapies and unlock new possibilities for treating a wide range of genetic disorders and diseases.

Emerging Therapeutics Showcase:
Envoya
Envoya's mission is to revolutionize the treatment landscape for diseases such as cancer and rare disease by leveraging the power of biocompatible delivery nanoparticles that are tailored for unique payloads and specific target tissue.

Biography
Dr. Mohindru has served as Novasentas Chief Executive Officer and Director since April 2021. Dr. Mohindru also serves as a Board member for two public companies (CytomX Therapeutics and Cardiff Oncology). Her prior Csuite experience includes being the CEO of CereXis, Inc., CFO and Chief Strategy Officer of Cara Therapeutics, and Chief Strategy Officer of Curis. Dr. Mohindru has also spent several years on Wall St. covering the biotech sector at UBS, Credit Suisse and ThinkEquity. On the nonprofit side, she is a member of the Executive Advisory Board of the Chemistry of Life Processes Institute of Northwestern University and a member of the Scientific Investment Advisory Committee of the Gates Center of Regenerative Medicine at the University of Colorado.

Emerging Therapeutics Showcase:
Novasenta
Novasenta discovers novel immuno-oncology therapeutic targets to develop innovative and effective treatments with the goal of transforming the lives of patients with cancer.

Biography
Maggie's current work focuses on characterizing the safety and in vivo characteristics of genome modifying enzymes for therapeutically relevant targets. She has also developed synthetic biology programs for CART cells using CRISPRi and CRISPRa. Maggie was a postdoctoral fellow at MGH and completed her graduate school studies at City of Hope.

Emerging Therapeutics Showcase:
Mammoth Bio
Mammoth Biosciences has built a broad portfolio of CRISPR technologies leveraging its protein discovery and engineering platform. The company is focused on developing its proprietary ultracompact CRISPR systems for in vivo gene editing in difficult to reach tissues to enable curative therapies.

Biography
Previously CEO of CMAB BioPharma, President of Pharmaceuticals of Simcere Pharmaceutical Group, CEO of Kanghong Biotech, and Staff Scientist at Genzyme Corporation. Led CMAB to become the fastest growing biopharmaceutical CDMO company in China, later acquired by WuXi Biologics in 2021.Managed a global team of more than 1,700 people and multiple commercialized companies at Simcere (publicly listed in HKEX).At Kanghong Biotech (publicly listed in China), first as head of CMC and quality and later as CEO, developed and marketed Conbercept, the first innovative biological drug with an INN to reach 1 billion RMB revenue in China and the first approved by the FDA to directly enter clinical phase III in 2016. At Genzyme responsible for the post-market maintenance of the first and second cell therapies approved by the FDA and the development of key CMC projects for the first FDA-approved tissue engineering product. Publications cited over 4,000 times.

Talk
Potentially BIC Gene Editing Product for ATTR
Our clinical data indicated that AccurEdits leading pipeline product (ART001) has the potential to be the best-in-class in vivo gene editing product for ATTR with 90% serum TTR reduction after 4 weeks, no off-target editing or DNA translocation at up to 80 times EC90, and no infusion-related reactions.

Emerging Therapeutics Showcase:
AccurEdit Therapeuti
AccurEdit Therapeutics has established an end-to-end in vivo gene editing platform and has become the first and only company to demonstrate safe and effective systemic CRISPR gene editing in humans in China.